Granata Bio has acquired Oviva Therapeutics Inc., a women’s health biotech company focused on advancing treatments that address female physiology, with an emphasis on ovarian aging. Oviva’s lead candidate, OVI-586, is a first-in-class therapeutic designed to enhance women’s health span—the period of life spent in optimal health—by extending ovarian function. OVI-586 holds potential applications across menopause, contraception, and in vitro fertilization (IVF), offering new p...